Cytokinetics, Inc. granted stock options and restricted stock units to 46 employees as inducement to employment. RSUs vest over 3 years, stock options over 4 years, subject to continued service. Options have exercise price of $38.67 per share. Cytokinetics is a specialty cardiovascular biopharmaceutical company advancing potential new medicines for heart conditions. The company is preparing for regulatory approvals for aficamten, a cardiac myosin inhibitor, following positive Phase 3 trial results in patients with hypertrophic cardiomyopathy. Cytokinetics is also developing other potential treatments for heart failure and muscular dystrophy. Forward-looking statements are included in the press release.

Read more at GlobeNewswire: Cytokinetics Announces Inducement Grants Under Nasdaq